Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers

Area of Science:

• Hepatology
• Medical Oncology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) incidence and mortality rates are increasing globally.
• Sorafenib was the sole U.S. Food and Drug Administration (FDA)-approved systemic therapy for HCC for over a decade.
• Since 2017, five new systemic agents have gained FDA approval for first- or second-line HCC treatment.

Purpose of the Study:

• To review current systemic therapy options for advanced HCC.
• To provide guidance on agent selection based on patient and tumor characteristics.
• To explore future directions for precision oncology in HCC.

Main Methods:

• Comprehensive literature review of clinical data for approved HCC systemic therapies.
• Analysis of agent-specific toxicity profiles, quality of life impacts, and monitoring strategies.
• Review of molecular and immunologic classifications of HCC and relevant preclinical data.

Main Results:

• Multiple systemic agents are now available for advanced HCC, offering alternatives to sorafenib.
• No clear guidelines exist for selecting the optimal agent based on individual patient or tumor factors.
• Each agent possesses a distinct toxicity profile and potential impact on patient quality of life.

Conclusions:

• The expanding landscape of HCC systemic therapies requires clear guidance for clinical decision-making.
• Understanding individual agent profiles and patient/tumor characteristics is crucial for effective treatment selection.
• Future research focusing on molecular/immunologic classifications and preclinical data may enable biomarker-driven precision oncology for HCC.